Except for abemaciclib, which can be used as monotherapy in refractory ER+/Her2- breast cancers [186], ribociclib and palbociclib are currently used in combination with aromatase inhibitors, or with fulvestrant for ER+ luminal breast cancers [182,187]. This evidence concerns the gene ESR1 and breast cancer.